Sort
10,766 grants matching “checkpoint inhibitor”
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
$587,093John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Drug eluting injectable biomaterials for next generation chemoembolization
$587,009Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2024 · CA
Evaluation of treatment predictors reflecting beta-catenin activation in hepatocellular carcinoma
$586,680Sandi Alexander Kwee · Queen'S Medical Center · R01 · FY2023 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
$586,358Alejandro V Villagra · George Washington University · R01 · FY2021 · CA
Engineering immunotherapeutic probiotics to mitigate irAE
$586,329Tal Danino · Columbia Univ New York Morningside · U01 · FY2020 · CA
Novel synthetic lethality strategy for TP53 mutant colorectal cancer
$585,984Christos Fountzilas · Roswell Park Cancer Institute Corp · R37 · FY2023 · CA
UCSF Project 1
$585,896Trever G Bivona · University Of California, San Francisco · U54 · FY2019 · CA
Preclinical development and clinical monitoring of adoptive immune therapy
$585,861Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2017 · CA
Regulation and Function of Stromal Macropinocytosis in Pancreatic Ductal Adenocarcinoma
$585,801Cosimo Commisso · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
$585,633Kevan C Herold · Yale University · R01 · FY2020 · CA
Systemic RNA Delivery to Tumors
$585,626Jinjun Shi · Brigham And Women'S Hospital · R01 · FY2021 · CA
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
$585,570Stephen H Safe · Texas A&M University · R01 · FY2023 · CA
Microtubule Regulation
$585,554Don W. Cleveland · Ludwig Institute For Cancer Res Ltd · R01 · FY2013 · GM
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
$585,317Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2025 · CA
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy
$585,212Baohua Zhou · Indiana University Indianapolis · R01 · FY2023 · CA
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy
$585,212Baohua Zhou · Indiana University Indianapolis · R01 · FY2025 · CA
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors
$584,926Seth M Pollack · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma
$584,891Shruthi Naik · Mayo Clinic Rochester · U01 · FY2022 · CA
Neutrophil derived proteinases abolish the IFNG signature in NSCLC
$584,823A. McGarry Houghton · Fred Hutchinson Cancer Center · R01 · FY2025 · CA
Strategies for Cancer Immunotherapy Development: Preclinical Studies
$584,740Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Decoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.
$584,631Nagireddy Putluri · Baylor College Of Medicine · R01 · FY2024 · CA
Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy andImmunotherapy
$584,575Bo Lu · University Of Missouri-Columbia · R01 · FY2024 · CA
Proteomic determinants of response to checkpoint blockade in malignant pleural mesothelioma
$584,543Bryan Michael Burt · University Of California Los Angeles · R37 · FY2024 · CA
Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer
$584,177Andrew Y Koh · Ut Southwestern Medical Center · R01 · FY2022 · CA
Engineering immunotherapeutic probiotics to mitigate irAE
$584,146Tal Danino · Columbia Univ New York Morningside · U01 · FY2022 · CA